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Immunohistochemical detection of advanced glycosylation end-prod-
ucts in the peritoneum and its possible pathophysiological role in CAPD.
It has recently been suggested that advanced glyeosylation end-products
(AGEs) are formed in the peritoneum in patients on CAPD. However, the
exact location of AGE accumulation, the relation with the duration of
CAPD and its pathophysiological role in CAPD remain unclear. If the
peritoneum is glycosylated, it could bring about altered peritoneal func-
tion. Therefore, the aim of this study is to clarify the localization of AGEs
in the peritoneum in accordance with the duration of CAPD and to
examine its relation to the peritoneal permeability. Fifteen non-diabetic
patients were divided into three groups (each 5 patients) on the basis of
the mean duration (D) of CAPD (Group I, D = 0 month; Group IT, D =
34 months; Group III, D = 84 months). The AGE staining by monoclonal
anti-AGE antibody in the peritoneum and the four-hour peritoneal
equilibration test (PET) were compared among these groups. AGE was
absent or found only weakly in Group I. However, in groups II and III,
AGE was moderately or strongly positive especially in the vascular walls
and it was dominant in group III. PET revealed that peritoneal perme-
ability for glucose, creatinine, 2-microglohulin and albumin was increased
in Group TI as compared to Group I, and it was further increased in Group
III. The results of this study indicate that AGEs become dominantly
accumulated in the vascular wall in accordance with the prolongation of
CAPD treatment, and this might play some roles for the increased
permeability of the peritoneal membrane in CAPD.
The advanced glycosylation end-product (AGE) is known as
one of major candidates to cause diabetic complications. Under a
hyperglycemic state, these products are derived from non-enzy-
matic glycosylation of long-lived proteins that arc further modi-
fied by the advanced stage of the Maillard reaction, resulting in
the formation of glucose-derived cross-links with a brown or
fluorescent property [1]. AGE increases vascular permeability by
several mechanisms, such as the disturbed integration of base-
ment membrane components due to the cross-linking of proteins
[2, 3], the endothelial cell reaction to the AGE receptor-mediated
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cytokine release from macrophage [4], or the occupancy of
endothelial cell AGE receptors [5].
In CAPD, it has been assumed that the high glucose of the
dialysate solution may facilitate glycosylation of the peritoneum.
Friedlander, Wu and Monnier [6] reported pentosidine, one of
AGEs, is detectable in the effluent, and its level is higher than that
of the blood. We previously reported that the peritoneum became
stained with monoclonal antibody against AGE 3 months after
CAPD was started [7]. These facts indicate that glycosylation of
the peritoneal components may actually occur during CAPD
treatment.
However, the exact location of AGE accumulation in the
peritoneum, its relation to the duration of CAPD treatment, and
its pathophysiological role in the CAPD treatment have not been
clearly determined. If the peritoneum is glycosylated by undergo-
ing CAPD, it could bring about altered peritoneal function.
Therefore, the aim of this study is to investigate (1) the relation-
ship between the location of AGE accumulation and the duration
of CAPD, and (2) the relationship between the AGE accumula-
tion and the solute transport of peritoneum.
Methods
Patients
Five patients with end-stage renal disease just before starting
CAPD and ten patients undergoing CAPD were studied. Patients
were divided into three groups according to the duration of
CAPD: Group I, five patients before starting CAPD due to
end-stage renal disease; Group II, five patients on CAPD for 20 to
48 months (average 34 months); Group III, five patients on CAPD
for 55 to 142 months (average 84 months) (Table 1). Patients who
had received regular hemodialysis or renal transplantation were
excluded from this study. The underlying renal diseases were: all
chronic gromcrulonephritis (CGN) in Groups I and III, 4 CGN
and one polycyctic kidney disease in Group II. Patients who had
diabetes mellitus or vasculitis related disorders were excluded. No
one had peritonitis during the period of observation. One case in
Groups II and Ill had two episodes of bacterial peritonitis more
than 24 months before this study. Patients on CAPD had been
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Table 1. Patient profiles
Group IIIGroup I Group II
N 5 5 5
Male/female 5/0 3/2 5/0
Ageyears 49 2 43 2 49 3
Duration of CAPD 0 34 7 84 16
months
Urinary volume mi/day 580 183 280 212 0 0
Hematocrit % 24.3 2.4 34.2 2.1 35.3 3.5
Creatinine mg/dl 11.6 2.1 12.4 0.6 10.6 0.7
fJ2m p.g/ml 28.9 3.2 35.4 3.9 34.8 0.6
HbAlc mg/dl 5.4 0.2 5.8 0.4 5.8 0.3
FBS mg/dl 83 5 87 8 84 3
Data arc mean SE. Abbreviation is FBS, fasting blood glucose level.
No significant differences were found in the age and laboratory data
except for the duration of CAPD, the daily urinary volume and the
hematocrit levels among three groups.
changing 2-liter bags four to five times daily (Dianeal PD-4; Japan
Baxter Ltd., Tokyo, Japan). No significant differences were found
in the patients profile or laboratory data such as the levels of
serum creatinine, ,!32-microglobulin (f32m), fasting blood glucose
level and HbAlc among three groups, except for the hematocrit
levels, the duration of CAPD and the daily urinary volume.
AGE immunoreactivily of peritoneum
Peritoneum was obtained when the CAPD catheter was in-
serted or re-inserted because of catheter-related problems, such
as severe skin tunnel infection or catheter obstruction. Informed
consents were obtained from all patients. The peritoneum ob-
tained was rapidly frozen on dry ice; frozen tissue sections were
thaw-mounted onto slides coated twice with gelatin and stored at
—80°C until use.
The peritoneum was stained with monoclonal anti-AGE anti-
body against AGE-bovine serum albumin (BSA) as described
previously [8]. Briefly, BSA was dissolved with D-glucose, and
incubated at 37°C for 90 days. This AGE-BSA, which showed the
absorbance and fluorescent spectra identical with those reported
elsewhere, was injected to immunize Balb/c mice. The lympho-
cytes from the immunized mouse were fused to myeloma P3U1
cells, and the specific cell lines producing antibodies which react
with AGE-BSA as well as human serum albumin (HSA) were
prepared. The subclass of these monoclonal antibodies were
determined as IgGi. One of these monoclonal antibodies was
used in the present study. This antibody reacted with AGE-BSA,
AGE-I-ISA and AGE-hemoglobin, but not with their native
counterparts. This antibody did not react with early products of
the Maillard reaction, such as Schiff base adducts and Amadori
rearrangement products.
Immunostaining using X500 diluted antibody was carried out
by the method using labeled streptavidin biotin. Negative control
staining was also performed using the antibody incubated with an
excess of antigen (1.5 p.g/ml as AGE-BSA) and no staining was
confirmed in any preparation.
The light-microscopical sections were examined for the local-
ization of AGE staining, particularly in the mesothelial layer,
vascular wall and connective tissue in each patient. Staining
intensity was graded semiquantitatively from 0 to 3, with 0
representing for negative, 1 for weak, 2 for moderate and 3 for
strong staining.
Peritoneal equilibration test
In each patient the peritoneal equilibration test was performed.
The peritoneal cavity was drained allowing more than 30 minutes
for complete drainage. Then a warmed two-liter solution (Dianeal
PD-4, 2.5% Dextrose) was infused. Soon after that, the peritoneal
cavity was drained allowing more than 30 minutes in order to
accomplish complete drainage and washout the residual effluent.
Thereafter, a warmed two-liter solution (Dianeal PD-4, 2.5%
dextrose) was infused. The dialysate was left in place for exactly
240 minutes, and then drained completely. In respective patients,
the solutes level of the plasma and effluent such as creatinine (Cr),
glucose, 132m and albumin (AIb) were measured. The DIP ratios
(Cr, /32m, AIb) and the D/D0-glucose were determined.
Statistical analysis
The results arc presented as mean SE. Differences between
groups were assessed by analysis of variance, with Bonferroni's
correction for multiple comparisons with a commercial program
(Statview). The D/D-glucose and the DIP-ratios were determined
by the following formula; DID0-glucose = [the glucose level of the
effluent (mgldl)12270], DIP-Cr = [the Cr level of the effluent
(mgldl)Ithe plasma Cr level (mg/dl)], D/P-2m = [2m effluent
level (/.Lg/ml)I2m plasma level (.tgIml)] x 10, D/P-Alb = [AIb
effluent level (j.gIml)IAlb plasma level (gIdl) x 100.
Results
Immunohistochemical analysis revealed that AGE staining was
very little or only weakly positive in Group I (Fig. 1 and 2). In
Group II, the mesothelial layers were stained in various degree of
intensity ranging from absent to moderate, indicating inconsistent
staining pattern. On the other hand, the staining of AGE in the
vascular walls was moderately positive in all cases. In connective
tissues, AGE was found weak to moderate (Figs. 3 and 4). In the
Group III, the mesothelial layers showed inconsistent staining
pattern ranging from absent to moderate, as in Group II. In the
vascular wall as well as the coarse connective tissue, moderate to
strong AGE stainings were found in all cases (Figs. 5 and 6).
The scores of AGE staining of the respective location in the
respective groups were shown in Figure 7. In the mesothelial
layer, the grade of immunostaining was low in Group I, and the
intensity increased in Groups II and III, however, this was not
statistically significant (0.2 0.2 in Group 1, 0.8 0.4 in Group
II and 1.4 0.4 in Group III, respectively). In the vascular wall,
the grade was low in Group I, and the highest in Group III. There
were significant differences between Groups II, III and Group I
(P 0.0006 and P < 0.0001, respectively; 0.8 0.2 in Group I,
2.0 0.0 in Group II and 2.6 0.2 in Group III, respectively). In
connective tissue, the grade was low in Group I and the highest in
Group III. There were significant differences between Groups III
and I (P < 0.0001), as well as between Groups II and III (P =
0.0067; 0.4 0.2 in Group 1, 1.2 0.2 in Group II and 2.2 0.2
in Group Ill, respectively). Overall, the grade was the highest in
the vascular walls in the respective groups.
The DID0-glucose and DIP ratios in the respective groups were
shown in Figure 8. The D/D0-glucose was lowest in Group III.
There was a significant difference between Groups II, III and
Group I (P < 0.0001 and P 0.0078, respectively; 0.41 0.02 in
Group 1, 0.32 0.04 in Group II and 0.21 0.02 in Group III,
respectively). The DIP-Cr was the highest in Group III. There
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Fig. 1. Peritoneum of a patient in Group I (S.K., 49-year-old male; X100). The peritoncum was not stained with monoclonal anti-AGE antibody except
for limited areas of the connective tissues, which was weakly positive (arrow).
Fig. 2. Peritoneum of a patient in Group I (N.K., 41-year-old male; X100). AGE was weakly positive in mesothelial layers and one of the vascular walls
(arrows).
Fig. 3. Peritoneum of a patient in Group II (S.F., 42-year-old frmale; X100). The stainings of mesothelial layers or connective tissues were not evident,
but AGE was moderately positive in vascular walls (arrows).
Fig. 4. Peritoneum of a patient in Group II (KY, 40-year-old male; X200). AGE was weakly positive in connective tissues. Moderately positive AGE was
found in mcsothelial layers as well as vascular walls (arrows).
Fig. 5. Peritoneum of a patient in Group III (F.S., 51-year-old male; Xl00). Moderate to strong AGE stainings were found in mesothelial layers as well
as vascular walls.
Fig. 6. Peritoneum of a patient in Group III (0. Y, 47-year-old male; )< 100). Strong AGE stainings were found in connective tissues.
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Fig. 8. The DID and DIP ratios in the respective groups (4-hour
PET). Data are presented as mean so. Symbols are: () DIP-Cr; ()
D/D0-glueose; () DP-p,m (x10); () DIP-AIb (xl02). The DID0-
glucose; Groups II vs. I, *JJ = 0.0078; Group III vs. I, < 0.0001. The
DIP-Cr: Groups I vs. III, *P = 0.0078. The DIP-/32m: Groups III and I,
0.0056. The DIP-AIb: Groups III and I 5P = 0.0045.
were significant differences between Groups I and III (P = 0.0078;
0.59 0.03 in Group 1, 0.71 0.06 in Group II and 0.83 0.06
in Group Ill, respectively). These PET results classified the
peritoneal permeability of respective groups as "low average" for
Group I, "high average" for Group II, and "high" for Group III.
The D/P-2m was the highest in Group III. There was a significant
difference between Groups I and III (P = 0.0056; 0.77 0.10 in
Group 1, 1.35 0.38 in Group II, and 2.14 0.31 in Group III,
respectively). The D/P-Alb was the highest in Group III. There
was a significant difference between Groups I and III (P = 0.0045;
0.72 0.08 in Group I, 1.32 0.30 in Group II and 1.90 0.28
in Group III, respectively).
Discussion
The results of this study showed the followings; (1) The
immunohistochemical study using anti-AGEs monoclonal anti-
body revealed that AGEs actually accumulated in the peritoneal
tissues with CAPD treatment, and it became apparent in accor-
dance with the prolongation of CAPD. Dominant accumulations
were also found in the vascular walls in patients on CAPD. (2)
The peritoncal permeability of various solutes, from small to large
molecules, were increased in accordance with the prolongation of
CAPD.
These results actually indicated that AGEs accumulated in the
peritoneum of patients on CAPD. Furthermore, they were in
accordance with the duration of CAPD. In patients on long-term
CAPD, their peritoneal cavity had been exposed to high levels of
glucose for long time. In addition to this, their residual renal
function, which is the main route for AGEs excretion [91, was
severely deteriorated. Thus, their plasma AGEs levels may he
increased. In fact, several studies revealed that the plasma AGEs
level are actually increased in patients on chronic dialysis treat-
ment [101 including CAPD [11, 121. These factors might, at least
partly, contribute to the stronger accumulation of AGEs in the
peritoneum of these patients.
The peritoneal permeability is increased during peritonitis, and
it has been suggested that the release of cytokines due to
inflammatory reaction has some roles for this mechanism [131. In
the present study, the peritoneal permeability of patients on
CAPD was significantly increased, as compared to the control
group, although no one had peritonitis during the period of
observation. Thus the mechanisms to increase the peritoneal
permeability should be attributed to factors other than peritonitis.
Since AGEs staining was evident in the vascular walls in these
patients, several mechanisms could be considered for the in-
creased peritoneal permeability. Cross-linking of basement mem-
brane components by AGEs such as laminin and heparan sulfate
proteoglycan or type IV collagen disturbs the integration of
basement membrane [2, 3], which increase vascular permeability.
On the other hand, the vascular endothelium have AGE recep-
tors. It is reported that its occupancy induces an increase in
permeability of vascular wall [5j. Accordingly, it is possible that
the accumulation of AGEs in the vascular walls of these patients
might play a role for the increased permeability of peritoncum of
CAPD patients. In Group Ill there was a tendency to increase in
the peritoncal permeability as compared to the Group II. Since
AGEs staining of the connective tissue in Group Ill was stronger
than that of Group II, the accumulation of AGEs in the connec-
tive tissues as well as in vascular walls might have some roles for
the increased peritoneal permeability.
This study shows that AGEs become dominantly accumulated
in the vascular wall ill accordance with the prolongation of CAPD
treatment, and this might play some roles for the increased
permeability of the peritoneal membrane in CAPD patients. The
result of this study indicates that the manipulation to inhibit or
reduce AGEs formation such as pharmacological intervention,
aminoguanidine [II or altered dialysate solution, low glucose
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Fig. 7. The scores of AGE stainings in the respective groups. Data are
presented as mean so. Symbols are: (El) group I; () group II; ()
group III. In vascular wall: Groups II vs. I, *p = 0.0006; Groups III vs. I,
**p < 0.0001, respectively. In connective tissue: Groups III vs. I, p <
0.0001; Groups II vs. III, = 0.0067.
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level solution [15j, may provide a new therapeutic strategies for
the preservation of peritoneal function in long-term CAPD
treatment.
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